According to a recent LinkedIn post from Phantom Neuro, the company plans to participate in The Montgomery Summit 2026 in Santa Monica, California, next month. The post indicates that Founder and CEO Connor Glass is scheduled to present the firm’s Phantom X minimally invasive neural interface on March 11, 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that Phantom X is designed to sit beneath the skin, decode muscle signals, and, with AI support, enable intuitive control of prosthetic limbs. The content suggests that the system has already shown high-accuracy, low-latency decoding of hand and wrist movements in real time, positioning the technology as a potential advance in human–machine interaction.
For investors, the upcoming conference presentation may offer increased visibility among growth-oriented and technology-focused investors and partners that typically attend The Montgomery Summit. Demonstrated performance metrics around accuracy and latency, if substantiated in a broader setting, could strengthen Phantom Neuro’s positioning within the neurotechnology and AI-in-healthcare segments.
The focus on minimally invasive interfaces and prosthetics control points to potential applications across medical devices and rehabilitation markets, which are often attractive for long-term, innovation-driven capital. While the post is promotional in nature and does not provide financial details, it may signal that Phantom Neuro is actively seeking to build strategic relationships, validate its technology, and possibly prepare for future funding or commercialization initiatives.